Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: A prospective longitudinal study

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1506-1510

  Devauchelle Pensec, Valérie ^a,b   Berthelot, Jean Marie ^c   Cornec, Divi ^a,b   Renaudineau, Yves ^b   Marhadour, Thierry ^a   Jousse Joulin, Sandrine ^a,b   Querellou, Solène ^d   Garrigues, Florent ^a   De Bandt, Michel ^e   Gouillou, Maelenn ^f   Saraux, Alain ^a,b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Universite de Brest   (France)

^c HÔTEL DIEU   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e Rheumatology Department   (France)

^f INSERM   (France)

Author keywords

Disease Activity; DMARDs (biologic); Magnetic Resonance Imaging; Polymyalgia Rheumatica; Treatment

Indexed keywords

PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; INFECTION; INSOMNIA; LEUKOPENIA; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUTROPENIA; OPEN STUDY; OPPORTUNISTIC INFECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATIC POLYMYALGIA; RHEUMATIC POLYMYALGIA ACTIVITY SCORE; TUBERCULOSIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; POLYMYALGIA RHEUMATICA; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREDNISONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84960859365     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208742     Document Type: Article

References (20)

1. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010;49:186-90.
2. De Bandt M. Current diagnosis and treatment of polymyalgia rheumatica. Joint Bone Spine 2014;81:203-8.
3. Kremers HM, Reinalda MS, Crowson CS, et al. Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 2005;53:578-84.
4. Naranjo A, López R, García-Magallón B, et al. Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica. Rheumatol Int 2014;34:1459-63.
5. Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: A systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 2015;74:1808-17.
6. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015;74:1799-807.
7. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500.
8. Hagihara K, Kawase I, Tanaka T, et al. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 2010;37:1075-6.
9. Izumi K, Kuda H, Ushikubo M, et al. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open 2015;1:e000162.
10. Toussirot É, Martin A, Soubrier M, et al. Rapid and sustained response to tocilizumab in patients with polymyalgia rheumatica resistant or intolerant to glucocorticoids: A multicenter open-label study. J Rheumatol 2016;43:249-51.
11. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63:1279-83.
12. Leeb BF, Rintelen B, Sautner J, et al. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 2007;57:810-15.
13. Binard A, de Bandt M, Berthelot JM, et al. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 2008;59:263-9.
14. Binard A, Lefebvre B, De Bandt M, et al. Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis 2009;68:541-5.
15. Cleuziou C, Binard A, De Bandt M, et al. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol 2012;39:310-13.
16. Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: A 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
17. Dasgupta B, Salvarani C, Schirmer M, et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008;35:270-7.
18. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012;71:484-92.
19. Carmona FD, Mackie SL, Martin JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet 2015;96:565-80.
20. Dejaco C, Duftner C, Cimmino MA, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011;70:447-53.